0001209191-17-007053.txt : 20170202
0001209191-17-007053.hdr.sgml : 20170202
20170202160305
ACCESSION NUMBER: 0001209191-17-007053
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20170131
FILED AS OF DATE: 20170202
DATE AS OF CHANGE: 20170202
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: bluebird bio, Inc.
CENTRAL INDEX KEY: 0001293971
STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
IRS NUMBER: 000000000
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 150 SECOND STREET
CITY: CAMBRIDGE
STATE: MA
ZIP: 02141
BUSINESS PHONE: 339-499-9300
MAIL ADDRESS:
STREET 1: 150 SECOND STREET
CITY: CAMBRIDGE
STATE: MA
ZIP: 02141
FORMER COMPANY:
FORMER CONFORMED NAME: Genetix Pharmaceuticals Inc
DATE OF NAME CHANGE: 20040616
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Mandell James
CENTRAL INDEX KEY: 0001595896
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-35966
FILM NUMBER: 17568279
MAIL ADDRESS:
STREET 1: GOODWIN PROCTER LLP
STREET 2: 53 STATE STREET
CITY: BOSTON
STATE: MA
ZIP: 02109
4
1
doc4.xml
FORM 4 SUBMISSION
X0306
4
2017-01-31
0
0001293971
bluebird bio, Inc.
BLUE
0001595896
Mandell James
C/O BLUEBIRD BIO, INC.
150 SECOND STREET
CAMBRIDGE
MA
02141
1
0
0
0
Common Stock
2017-01-31
4
M
0
8000
21.43
A
9000
D
Common Stock
2017-01-31
4
S
0
8000
75.0402
D
1000
D
Stock Option (right to buy)
21.43
2017-01-31
4
M
0
8000
0.00
A
2024-01-08
Common Stock
8000
4000
D
This sales reported in the Form 4 were effectd pursuant to a 10b5-1 trading plan adopted by the reporting person on December 13, 2016.
The range in prices for the transaction reported on this line was $75.00 to $75.20. The average weighted price was $75.0402. The reporting person will provide, upon request by the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price.
This option vests ratably over three years in annual installments, commencing on January 8, 2014.
/s/ Jason F. Cole, Attorney-in-Fact
2017-02-02